CASE REPORT

Deep sequencing reveals persistence of cell-associated mumps vaccine virus in chronic encephalitis

Sofia Morfopoulou1 · Edward T. Mee2 · Sarah M. Connaughton2 · Julianne R. Brown3 · Kimberly Gilmour4 · WK ‘Kling’ Chong5 · W. Paul Duprex6 · Deborah Ferguson2 · Mike Hubank7 · Ciaran Hutchinson8 · Marios Kaliakatsos9 · Stephen McQuaid10,11 · Simon Paine8,12 · Vincent Plagnol13 · Christopher Ruis1 · Alex Virasami8 · Hong Zhan14 · Thomas S. Jacques8,15 · Silke Schepelmann2 · Waseem Qasim16,17 · Judith Breuer1,3

Received: 11 August 2016 / Revised: 4 October 2016 / Accepted: 4 October 2016 / Published online: 21 October 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract Route childhood vaccination against measles, mumps and rubella has virtually abolished virus-related morbidity and mortality. Notwithstanding this, we describe here devastating neurological complications associated with the detection of live-attenuated mumps virus Jeryl Lynn (MuVJL5) in the brain of a child who had undergone successful allogeneic transplantation for severe combined immunodeficiency (SCID). This is the first confirmed report of MuVJL5 associated with chronic encephalitis and highlights the need to exclude immunodeficient individuals from immunisation with live-attenuated vaccines. The diagnosis was only possible by deep sequencing of the brain biopsy. Sequence comparison of the vaccine batch to the MuVJL5 isolated from brain identified biased hyper-mutation, particularly in the matrix gene, similar to those found in measles from cases of SSPE. The findings provide unique insights into the pathogenesis of paramyxovirus brain infections.

Introduction

Chronic encephalitis with progressive loss of motor and cognitive function and high levels of intrathecal antibodies has been associated with persistent measles and rubella infections of the brain, most commonly in the context of...
subacute sclerosing pan-encephalitis (SSPE). We describe here a case of chronic panencephalitis in a child who had undergone successful allogeneic haematopoietic stem cell transplantation (allo-SCT) for severe combined immunodeficiency (SCID) in whom neither measles nor other pathogens could be detected. Using deep sequencing of fresh brain biopsy material, we identified the Jeryl Lynn 5 mumps virus (MuVJL5), a component of the measles, mumps, rubella (MMR) vaccine that had been administered to the child before the diagnosis of SCID. Similar to findings in measles viruses recovered from cases of SSPE, the mumps virus genome from the brain showed evidence of biased hypermutation, particularly in the matrix (M) gene. Comparison with sequence data from the original vaccine batch used to immunise this child identified the expansion of variants present at low frequency in the vaccine as well as de novo fixed missense substitutions. This case represents the first conclusive demonstration of chronic panencephalitis due to mumps virus.

Case report

An 18-month-old male infant of consanguineous parents was diagnosed with SCID due to recombinase activating gene 1 (RAG1) deficiency (Fig. 1a) 4 months after MMR vaccination. The infant received a CD34-selected haploidentical allo-SCT. Full donor chimerism was rapidly achieved, with recovery of a diverse T cell repertoire (Fig. 1a) and excellent thymopoiesis. Post-transplant autoimmune cytopenias necessitated rituximab therapy, following which immunoglobulin replacement therapy was administered. Six months post-allo-SCT the child developed a febrile illness with rash, diarrhoea, lethargy and seizures, with evidence of encephalitis on magnetic resonance imaging (MRI) with raised CSF protein (1.35 g/L) and 11 lymphocytes. Despite extensive screening for neurotropic viruses and bacteria (Table S1), no pathogen was detected. He was treated with antimicrobials, antivirals and steroids, making a good recovery, and was discharged on antiepileptic treatment, but he remained stable for another 9 months. Repeat MRI scan 2 years after initial encephalitic illness showed no new lesions. Over the next few months, the child’s neurological condition deteriorated, with increasing seizures together with episodes of lethargy, disorientation, agitation, ataxic gait, visual loss and eventual hospitalisation.

Repeat MRI of the brain at 40 months post-allo-SCT revealed abnormalities of grey and white matter, involving both cerebral hemispheres with multiple foci of contrast enhancement, including the basal ganglia, temporal and parieto-occipital cortices (Fig. 1b). In the absence of a firm diagnosis, a brain biopsy was taken.

Broad-spectrum antibiotics, aciclovir, ganciclovir and antifungal therapy were administered, as well as intravenous immunoglobulin (IVIG) and high-dose methyl prednisolone. Increasing seizures, left-sided weakness, cortical blindness and progressive global neurological deterioration over several weeks ended with the patient’s death 7 weeks following his last hospital admission.

Materials and methods

PCR assays

The viruses listed in Table S1 were tested for using real-time PCR and found to be negative using specific primers and TaqMan probes on an ABI 7500 thermocycler. All PCR assays were performed in-house at GOSH (Great Ormond Street Hospital for Children, London) as part of the routine diagnostic service, unless indicated otherwise, in which case they were sent to a different laboratory for testing.

The CSF and urine samples collected during the patient’s last hospitalisation, as well as RNA re-extracted from the brain biopsy, were sent to the Public Health England Virus Reference Laboratory (Colindale) for mumps and mumps vaccine-specific RT-PCR (targeting the SH and HN gene) as well as measles and rubella-specific RT-PCR.

Sequencing

Library preparation—brain biopsy

Total RNA was purified from the frozen brain biopsy and polyA RNA-separated for sequencing library preparation. Samples were sequenced on the Illumina NextSeq500
instrument (Illumina, San Diego, US) using an 81 bp paired-end run. Libraries to be multiplexed in the same run were pooled in equimolar quantities, calculated from qPCR and/or Bioanalysyer fragment analysis.

Samples were processed using Illumina’s TruSeq Stranded mRNA LT sample preparation kit (p/n RS-122-2101) according to the manufacturer’s instructions. Deviations from the protocol were as follows: (1) 250 ng total RNA was used as starting material. (2) Fragmentation was carried out for 10 min instead of 8 min. (3) 14 Cycles of PCR were used.

Briefly, mRNA was isolated from total RNA using oligo dT beads to pull down poly-adenylated transcripts. The purified mRNA was fragmented using chemical fragmentation (heat and divalent metal cation) and primed with random hexamers. Strand-specific first-strand cDNA was generated using SuperScript II Reverse Transcriptase (Life Technologies) and actinomycin D. This allows RNA-dependent synthesis while preventing spurious DNA-dependent synthesis. The second cDNA strand was marked by performing synthesis incorporating dUTP.

The cDNA is then “A-tailed” at the 3’ end to prevent self-ligation during the addition of the full-length TruSeq Adaptors (adaptors have a complementary “T” overhang). The adaptors contain sequences that allow the libraries to be amplified by PCR, bind to the flow cell and be uniquely identified by way of a 6 bp index sequence. Finally, a PCR is carried out to amplify only those cDNA fragments that have adaptors bound to both ends.

**Library preparation—vaccine**

An archived vial from the batch of MMR vaccine used to immunise the child was deep sequenced in a 2 × 251 paired-end sequencing on an Illumina MiSeq as part of a 16-sample pool, generating 1,570,733 read pairs, at the National Institute for Biological Standards and Control (NIBSC).

Lyophilised vaccine was re suspended in 500 µl sterile water for injection and viral RNA extracted using the QIAamp Viral RNA Mini Spin Kit (Qiagen) according to the method of the manufacturer, with the omission of carrier RNA. DNA libraries were prepared by random reverse-transcriptase polymerase chain reaction as described previously [18], followed by fragmentation, adaptor addition and indexing using the Nextera XT library preparation kit (Illumina).

**Immunohistochemistry**

Formalin-fixed paraffin-embedded sections of brain biopsy were examined by conventional histology. Immunohistochemistry was undertaken using two different antibodies in two independent laboratories.

Immunohistochemistry was undertaken using mumps nucleoprotein (N) antibody (7B10: sc-57921 Santa Cruz) at 1 in 25 using a Leica Bond Max automated staining system with pretreatment HIER (30) ER2. Additional immunohistochemistry was independently undertaken using a different antibody. The monoclonal mumps antibody used [16] recognises the N protein of MuV (N93-51/01) and was used on an automated Leica BondMax immunostainer at a dilution of 1/4000 following HIER2 pre-treatment for 20 min. Detection sites were detected with a polymer-based detection system (Bond, Newcastle upon Tyne, UK, Cat. No. DS9800). Detection of mumps N in the CNS by immunohistochemistry is shown in Figure S2.

**Bioinformatics analysis**

For the analysis of the brain biopsy sequencing data, we implemented the following steps. We first removed duplicate sequences that can arise from PCR amplification with an in-house script that collapses pairs of reads based on sequence identity using 90 % of the sequence as signature (20 % removed as duplicates). Half of the reads overlapped with their “mates” within pairs and we therefore merged the overlapping reads using PEAR [32], taking into account both sequence match and quality scores. We performed quality control using PrinSeq [25], trimming low-quality ends and removing reads that had average quality less than 15. We subsequently removed human sequences, using a quick aligner (Novoalign version V2.07.13—human reference genome GRCh37) as well as BLASTn [2]. We performed de novo assembly of high-quality contigs using Velvet [31] (kmer = 81). Finally, we annotated the contigs and the unassembled reads against a custom protein reference database using BLASTx. Our custom protein reference database consists of viral, bacterial, human and mouse RefSeq proteins. More specifically, all known viruses in the RefSeq collection are used ftp://ftp.ncbi.nlm.nih.gov/refseq/release/viral/viral.1.protein.faa.gz, as well as all the bacteria of the human microbiome, according to ftp://ftp.ncbi.nih.gov/genomes/HUMAN_MICROBIOM/Bacteria/all.faa.tar.gz. The BLASTx results were the input of metaMix [21].

For the analysis of the vaccine sequencing, we first removed 15 % of the reads as duplicates and merged overlapping reads. We trimmed the reads based on base quality \(q = 20\) using Trim Galore! (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). We then selected for Jeryl Lynn vaccine strain reads using BLASTn [2] and a Jeryl Lynn nucleotide reference database.

We performed de novo assembly with SPADEs [4] followed by QUAST [12] for both the vaccine and the brain sequencing data. In the latter case, we used the MuV reads as identified by metaMix [21]. Novoalign, Samtools [17]
and VarScan2 [15] were used for consensus sequence generation and variant calling. We filtered variants based on quality, depth, frequency and strand bias (quality $\geq 30$, at least 5 reads for the variant site, frequency $\geq 5\%$, p value <0.01). The variants were annotated with SnpEff [7].

We compared the number of non-synonymous changes observed in each of the MuV genes to the number we would expect if the observed missense mutations were randomly distributed across the genome, correcting for the gene length. Significant deviation from the expected number of mutations was tested with the goodness-of-fit two-tailed exact binomial test. Analysis was conducted with the statistical language R (http://www.r-project.org).

We estimated a maximum likelihood phylogenetic tree using RAxML [27] and 64 full MuV genomes from GenBank (accessed on 20 June 2015).

Results

CSF on last admission was acellular, but with oligoclonal bands, although total protein was low 0.12 g/L (normal 0.15–0.45 g/L). The oligoclonal bands were negative for HSV and VZV antibodies. Polyoma JC virus was detected by PCR in blood and urine on one occasion each (Table S2). CSF PCR was negative for 16S (bacterial) and 18S (fungal) rRNA and for a wide number of viral pathogens (Table S2), including JC virus, mumps, measles and rubella viruses. No pathogens were detected in stool, urine or blood (Table S2). CSF was negative for rubella and measles antibodies. In the absence of a firm diagnosis, a brain biopsy confirmed the presence of MuVNL5 vaccine strain (Table S2), but was negative for all other viruses, including polyoma JC (Table S2). Immunohistochemistry showed the presence of MuV nucleocapsid (N) protein with a neuronal pattern of staining (Fig. 2g, h). Control cortex and white matter were negative. We observed no specific staining for other pathogens (Fig. 2g,h for details) and no evidence of viral intracytoplasmic or intranuclear inclusion bodies. Retrospective testing showed weakly positive mumps antibody in the CSF.

To investigate this finding further, three million 251 bp paired-end reads were generated from the MMR vaccine batch that was used to immunise the child, of which 82,000 reads mapped to the MuVNL5 vaccine strain (median coverage: 706, Figure S1). There were no fixed differences identified compared with the reference FJ211585. Fifteen positions in the vaccine sequence were found to be polymorphic (variant allele frequency (VAF) 5 % or greater, Table S4).

Of 55 fixed nucleotide differences between MuVNL5-London and the vaccine, 12 had been present as a minority variant (10–24 %) in the vaccine (Figure S3, Table S4, VAF 75 % or greater). Of the remaining 43 new mutations, 28 coded for missense amino acid substitutions (Fig. 3, Table S5), with nine (32 %) located in the M protein, more than expected by chance (two-tailed exact binomial test $p = 2.8e^{-04}$, Table S6). Other than position 140 in the M protein, the missense mutations were unique to MuVNL5-London (Figure S6). The Tyr140His substitution in MuVNL5-London is found in all wild-type strains as well as the more neurovirulent MuVUL5 Urabe and the MuVNL2 Jeryl Lynn 2 vaccine strain, which is a minor component of some vaccines [1] (Figure S6).

Discussion

Prior to the introduction of routine MMR vaccination, mumps virus was the commonest cause of meningoencephalitis in children and was associated with serious sequelae including deafness and orchitis [11, 22]. No meningoencephalitis has been confirmed following the Jeryl Lynn mumps vaccine, which this child received, and other adverse effects are rare [19] and usually self-limiting [14]. Mumps and rubella vaccine virus transcripts were detected in the brain of a child with IFNAR2 deficiency who developed fatal encephalitis following MMR vaccination [9], but brain immunohistochemistry was negative in this case (JB personal communication).
The presentation of this case, shares features with two previously published cases of MuV-related progressive encephalitis [13, 28]. Moreover, like measles SSPE and measles inclusion body encephalitis (MIBE) [29], which occurs in immunocompromised children within months of measles infection or vaccination, and unlike acute MuV encephalitis, no virus was detected in the CSF. However, other hallmarks of SSPE and MIBE such as high virus-specific antibody levels in CSF [29], were absent, although the child had deficient B cell function.

Importantly, however, in comparison with MuV JL5 from the vaccine batch used to immunise the child, MuV JL5-London showed evidence of T to C biased hypermutation, particularly in the M (matrix) gene suggestive of adenosine deaminase (ADAR)-driven mutation [10] (Table S4). The same finding in MV recovered from SSPE and MIBE [6, **Fig. 2** Much of the cortex showed significant tissue damage with neuronal loss. There was prominent reactive gliosis composed of plump astrocytes with abundant eosinophilic cytoplasm and immunoreactivity for glial fibrillary acidic protein (GFAP) (a, e) with relative sparing of the superficial layers of the cortex. Some areas showed perivascular lymphocytosis and collections of macrophages (a, e). In others, with better neuronal preservation, there were foci of microglial nodules, neuronophagia, generalised microgliosis (demonstrated on CD68 staining b, d)) and patchy parenchymal and perivascular lymphocytes, the majority of which were positive for the T cell markers (f). Occasional foci of mineralisation were observed, but there was no vasculitis and no viral inclusions. The pathological changes extended into the underlying white matter (data not shown), which showed patchy loss of myelin staining on luxol fast blue. There was focal chronic inflammation in the leptomeninges. Mumps immunohistochemistry was positive in a neuronal pattern (g, h). We observed no specific staining for other pathogens HSV1 or 2, CMV, EBV, toxoplasma, JC virus, bacteria (Gram and Gram Twort), acid-fast bacteria (Ziehl-Neelsen) or fungi (Grocott), and no evidence of intracellular or intranuclear viral inclusion bodies. a, b Haematoxylin and eosin (H&E), c, d CD68 immunohistochemistry, e GFAP immunohistochemistry, f CD3 immunohistochemistry. Scale bars b, h 50 μm, a, c, d, e, g 100 μm, f 200 μm
29, 30] has been shown to reduce M protein expression [29] and is mooted to promote cell to cell spread and reduced viral assembly and shedding into the CSF. Biased hypermutation and lack of protein expression may also reflect the dispensability of M protein for neurovirulence [3].

MuVJL5-London was characterised by the expansion of variants present at low frequency in the original vaccine, two of which have previously been described [8], as well as fixed de novo mutations in the M, N, P, L and F genes, a finding which again references those described for MV in SSPE. While most amino acid substitutions occurred in the M gene, in vitro data using the rat model implicates the F protein [3, 16] as key for mumps virus neurovirulence in acute encephalitis [16, 24] as well as for measles neurovirulence in SSPE [3]. The absence of within-host sequence diversity in the M and F ORFs (Figure S5, Table S7) further suggests functional constraints on these genes and supports directional selection acting on one or more of the amino acid changes in these proteins favouring spread and replication of MuVJL5 in the brain.

In this child, clinical deterioration occurred following good T cell reconstitution in the context of normal T cell receptor repertoire and good levels of thymopoiesis. One possibility is that the presence of mumps tolerised and dysregulated T cell responses, thus permitting long-term viral persistence and the accumulation of pathogenic mutations. We made use of data on the donor’s HLA genotype to predict specific CTL cell epitopes (IEDB epitope prediction tool, percentile rank cutoff ≤ 1 %) in the MuVJL5 mumps vaccine virus. Five missense mutations were located in the predicted CTL epitopes for the donor’s HLA (Fig. 3, Table S8). Of these, four had predicted T cell binding affinities at a level likely to correlate with T cell recognition [26] and reduced binding affinity in the mutated peptide (Table S8). This raises the possibility that partial escape of virus from immune surveillance through specific mutational changes may have occurred, especially as the same was not observed for peptides recognised by randomly selected HLA alleles (Supplementary Appendix, Table S8).

In summary, we report a case of progressive chronic encephalitis in a patient with SCID, in which the MuVJL5 vaccine strain was detected in brain biopsy by deep sequencing. This case emphasises the generally poor rates of pathogen detection in encephalitides, making a strong case for deep sequencing of brain tissue where other methods have failed. The similar pattern of viral mutations in this case and those of measles SSPE suggest a common pathogenic process and further work is currently underway to determine the contribution of fixed mutations to the chronic encephalitic phenotype observed in the patient. It is important to note that MMR continues to be a highly effective and safe vaccine in the vast majority of individuals. However, this case highlights the importance of developing strategies such as newborn screening to exclude the very small proportion of infants at extremely high risk of complications from live-attenuated vaccines.

Fig. 3 Fixed (defined to have frequency greater than 75 %) missense substitutions in the MuVJL5-London brain mumps virus genome. The amino acid changes are plotted along the genome, colour-coded for each viral protein. The black dashed lines are the missense changes pre-existing as minor variants in the genome of the vaccine virus. The predicted CTL epitopes are also indicated.
Acknowledgments The authors acknowledge Public Health England (PHE) and Micropathology Laboratory Ltd. for PCR assays, as detailed in Supplementary Table 2 and Tony Brooks at UCL Genomics for sequencing services.

Financial disclosure This work was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH) and University College London. S.M. was funded by Pathseek FP7. J. Brown is supported by an NIHR fellowship and the GOSH/UCL BRC. W.Q received grant funding from NIHR, GOSH Charity, GOSH/UCL BRC. JB received funding from the NIHR BRC at University College London Hospitals (UCLH)/UCL. The remaining authors have nothing to disclose.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Afzal MA, Pickford AR, Forsey T, Heath AB, Minor PD (1993) The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. J Gen Virol 74(5):917–920. doi:10.1099/0022-2836-74-5-917
2. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215:403–410. doi:10.1016/0022-2836(90)90570-K
3. Ayata M, Tanaka M, Kameoka K, Kuwamura M, Takeuchi M, Takeda M, Kanou K, Ogura H (2016) Amino acid substitutions in the heptad repeat A and C regions of the F protein responsible for neurovirulence of measles virus Osaka-1 strain from a patient with subacute sclerosing panencephalitis. Virology 487:141–149. doi:10.1016/j.virol.2015.10.004
4. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA (2012) SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477. doi:10.1089/cmb.2012.0021
5. Brown JR, Morfopoulou S, Hubb J, Emmett WA, Ip W, Shah D, Brooks T, Paine SML, Anderson G, Virasami A, Tong CYW, Clark DA, Plagnol V, Jacques TS, Qasim W, Hubank M, Breuer J (2015) Astrovirus VA1/HMO-C: an increasingly recognized neurotropic pathogen in immunocompromised patients. Clinical Infect Dis 60(6):881–888. doi:10.1093/cid/ciu940
6. Cattaneo R, Schmid A, Eschle D, Baczko K, ter Meulen V, Billiter MA (1988) Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell 55:255–265. doi:10.1016/0092-8674(88)90048-7
7. Cingolani P, Platts A, Wang J, Coon M, Nguyen T, Wang L, Land SJ, Ruden DM, Lu X (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. Fly (Austin) 6(2):1–13. doi:10.4161/fly.19695
8. Connaughton SM, Wheeler JX, Vitková E, Minor P, Vitkova E, Minor P, Schepelmann S (2015) In vitro and in vivo growth alter the population dynamic and properties of a Jeryl Lynn mumps vaccine. Vaccine 33:4586–4593. doi:10.1016/j.vaccine.2015.06.109
9. Duncan CIA, Mohamad SMB, Young DF, Skelton AJ, Leahy TR, Munday DC, Butler KM, Morfopoulou S, Brown JR, Hubank M, Connell J, Gavin PJ, McMahon C, Dempsey E, Lynch NE, Jacques TS, Valappil M, Cant AJ, Breuer J, Engelhardt KR, Randall RE, Hambleton S (2015) Human IFNAR2 deficiency: Lessons for antiviral immunity. Sci Transl Med 7:307ra154–307ra154. doi:10.1126/scitranslmed.aac4227
10. Fehrholz M, Kendl S, Priftic C, Weissbrich B, Lemon K, Rennick L, Duprex PW, Rima BK, Koning FA, Holmes RK, Malim MH, Schneider-Schaulies J (2012) The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses. J Gen Virol 93:565–576. doi:10.1099/vir.0.038919-0
11. Galazka AM, Robertson SE, Kraigher A (1999) Mumps and mumps vaccine: a global review. Bull World Health Organ 77:3–14. doi:10.1007/BJ02727158
12. Gurevich A, Saveliev V, Vyakhri N, Tesler G (2013) QUAST: quality assessment tool for genome assemblies. Bioinformatics 29:1072–1075. doi:10.1093/bioinformatics/btt086
13. Haginoya K, Ike K, Inuma K, Yagi T, Kon K, Yokoyama HNY (1995) Chronic progressive mumps virus encephalitis in a child. Lancet 346:50
14. Hvid A, Rubin S, Mühlemann K (2008) Seminar: mumps. Lancet 371:932–944. doi:10.1016/S0140-6736(08)60419-3
15. Koboldt DC, Zhang Q, Larson DE, Shen D, Mcclellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK (2012) VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22(3):568–576. doi:10.1101/gr.129684.111
16. Lemon K, Rima BK, McQuaid S, Allen IV, Duprex WP (2007) The F gene of rodent brain-adapted mumps virus is a major determinant of neurovirolelence. J Virol 81:8293–8302. doi:10.1128/JVI.00266-07
17. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R (2009) The sequence alignment/map format and SAMtools. Bioinformatics 25:2078–2079. doi:10.1093/bioinformatics/btp352
18. Mee ET, Minor PD, Martin J (2015) High resolution identity testing of inactivated poliovirus vaccines. Vaccine 33:3533–3541. doi:10.1016/j.vaccine.2015.05.052
19. Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B (2007) Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. Am J Epidemiol 165:704–709. doi:10.1093/aje/kw045
20. Morfopoulou S, Brown JR, Davies EG, Anderson G, Virasami A, Qasim W, Chong WK, Hubank M, Plagnol V, Desforges M, Jacques TS, Talbot P, Breuer J (2016) Human coronavirus OC43 associated with fatal encephalitis. N Engl J Med 375:497–508. doi:10.1056/NEJMc1509458
21. Peltola H, Kulkarni PS, Kapre SV, Paunio M, Jadhav SS, Dhere RM (2007) Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clin Infect Dis 45:459–466. doi:10.1086/52028"
contributions to mumps virus neurovirulence and neuroattenuation. J Virol 85:7059–7069. doi:10.1128/JVI.00245-11
25. Schmieder R, Edwards R (2011) Quality control and preprocessing of metagenomic datasets. Bioinformatics 27:863–864. doi:10.1093/bioinformatics/btr026
26. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJ, Oseroff C, Yuan L, Ruppert J, Sidney J, del Guercio MF, Southwood S, Kubo RT, Chesnut RW, Grey HM, Chisari FV (1994) The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153:5586–5592
27. Stamatakis A (2014) RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics 30:1312–1313. doi:10.1093/bioinformatics/btu033
28. Vaheri A, Julkunen IKM (1982) Chronic encephalomyelitis with specific increase in intrathecal mumps antibodies. Lancet 2:685–688
29. Wilson MR, Ludlow M, Duprex WP (2013) Human paramyxoviruses and infections of the central nervous system. In: Singh SK, Ruzek D (eds) Neuroviral infect. CRC Press, USA, pp 341–372
30. Wong TC, Ayata M, Hiran A, Yoshihawa Y, Tsuruoka H, Yamanouchi K (1989) Generalized and localized biased hypermutation affecting the matrix gene of a measles virus strain that causes subacute sclerosing panencephalitis. J Virol 63:5464–5468
31. Zerbino DR, Birney E (2008) Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res 18:821–829. doi:10.1101/gr.074492.107
32. Zhang J, Kobert K, Flouri T, Stamatakis A (2014) PEAR: a fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics 30:614–620. doi:10.1093/bioinformatics/btt593